3 Stocks Whose Competitive Walls Tower Over Nvidia's
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
VRTX - Vertex Pharmaceuticals Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$560.92
DETAILS
HIGH:
$665.00
LOW:
$350.00
MEDIAN:
$580.00
CONSENSUS:
$560.92
UPSIDE:
2.71%
Stock News
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company's continued growth and diversification. Completion of Acquisition of Crinetic.
Ancora Advisors LLC Acquires Shares of 1,127 Vertex Pharmaceuticals Incorporated $VRTX
Ancora Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,127 shares of the pharmaceutical company's stock, valued at approximately $560,000. A number of other institutional investors
17,047 Shares in Vertex Pharmaceuticals Incorporated $VRTX Acquired by Beacon Pointe Advisors LLC
Beacon Pointe Advisors LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 17,047 shares of the pharmaceutical company's stock, valued at approximately $8,466,000. A number of other hedge funds have
Breakfast News: Nvidia Crushed It. Who Cares?
Nvidia revenue more than doubles, Okta and Veeva climb on beats, and more
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha Pai will also participate in a fireside chat at the 2026 Cantor G.
EP Wealth Advisors LLC Acquires New Position in Vertex Pharmaceuticals Incorporated $VRTX
EP Wealth Advisors LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 9,027 shares of the pharmaceutical company's stock, valued at approximately $4,484,000. Other institutional investors have also recently bought and
Advisors Capital Management LLC Buys Shares of 1,258 Vertex Pharmaceuticals Incorporated $VRTX
Advisors Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,258 shares of the pharmaceutical company's stock, valued at approximately $625,000. A number of other
Allworth Financial LP Invests $2.23 Million in Vertex Pharmaceuticals Incorporated $VRTX
Allworth Financial LP acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,487 shares of the pharmaceutical company's stock, valued at approximately $2,229,000. Several other institutional investors and hedge
Uber, ServiceNow And A Health Care Stock On CNBC's ‘Final Trades'
On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked ServiceNow, Inc. (NYSE:NOW).
In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?
VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. However, one of the company's most important potential competitors recently hit a clinical setback.
AssuredPartners Investment Advisors LLC Invests $2.06 Million in Vertex Pharmaceuticals Incorporated $VRTX
AssuredPartners Investment Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,147 shares of the pharmaceutical company's stock, valued at approximately $2,060,000. Several other institutional investors
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this considerati.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
Vertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area. The company is slowly developing and launching medicines in other markets.
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter and 10.6% year-on-year to about $3.21 billion in Q2. On July 6, VRTX announced the acquisition of Crinetics Pharmaceuticals for about $10 billion, thereby strengthening its position in the endocrinology drugs market.
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday
Its sales rose at a double-digit rate; net profit growth was more modest. There's another development with the company more worth monitoring, however.
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
Price Targets
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
$665.00
(was $547.65)
Terence Flynn
·
Morgan Stanley
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
$653.00
(was $544.52)
Goldman Sachs
Bernstein SocGen Reiterates Outperform Rating on Vertex (VRTX)
$608.00
(was $530.29)
Jeffrey Walch
·
Bernstein
Vertex (VRTX) PT Raised to $562 at Wolfe Research
$562.00
(was $522.78)
Andy Chen
·
Wolfe Research
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
$565.00
(was $488.56)
Truist Financial
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
$617.00
(was $478.70)
Barclays
Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald
$595.00
(was $470.72)
Cantor Fitzgerald
Vertex Pharmaceuticals price target raised to $442 from $430 at Canaccord
$442.00
(was $470.72)
Canaccord Genuity
Vertex Pharmaceuticals price target raised to $500 from $466 at Stifel
$500.00
(was $470.72)
Stifel Nicolaus
Vertex Pharmaceuticals price target raised to $585 from $545 at UBS
$585.00
(was $481.70)
UBS
Vertex Pharmaceuticals price target raised to $560 from $542 at Truist
$560.00
(was $479.01)
Truist Financial
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
$570.00
(was $529.59)
RBC Capital
Vertex Pharmaceuticals price target raised to $350 from $330 at Baird
$350.00
(was $529.59)
Robert W. Baird
Truist Securities Assumes Vertex (VRTX) at Buy
$542.00
(was $435.93)
Danielle Brill
·
Truist Financial
Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays
$615.00
(was $424.36)
Barclays
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
$616.00
(was $417.72)
Morgan Stanley
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
$543.00
(was $429.85)
Brian Abrahams
·
RBC Capital
Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
$572.00
(was $429.85)
Bernstein
Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
$436.00
(was $429.85)
Canaccord Genuity
Vertex Pharmaceuticals price target lowered to $437 from $441 at Canaccord
$437.00
(was $423.24)
Canaccord Genuity